Patients with advanced pancreatic cancer (APC) experience many disease-related symptoms. ESAS-r measures the severity of 9 symptom domains and has been validated for use in the ambulatory oncology setting. We aimed to describe symptom burden at baseline for patients with APC treated with modern chemotherapy (CT), and to determine whether symptom burden at baseline is prognostic. Patients diagnosed with APC between 2012–2016, treated with ≥1 cycle of CT, who completed ≥1 ESAS-r were identified. Descriptive statistics were used to report symptom burden and common moderate-to-severe symptoms. A joint model was used to describe the trajectory of ESAS-r during follow-up while controlling for death. Multivariable Cox regression was used to identify independent predictors of death. Of 123 patients identified, the median age was 65 and 61% had metastatic disease. The median baseline ESAS-r total symptom distress score (TSDS) was 24. A total of 86% of patients had at least one symptom score of ≥4 at baseline, with the most common being: fatigue, nausea, anxiety, and shortness of breath. Median overall survival was 10.2 months. Baseline TSDS was not predictive for worse survival in the era of modern CT. Patients with APC have a high burden of cancer-associated symptoms and a high prevalence of moderate-to-severe symptoms. Early intervention has the potential to improve quality of life in this group of patients and should be investigated.
Background Although the benefits of early palliative care have been established in advanced cancers, there remains a lack of access to and poor uptake of these services. Barriers include healthcare provider attitudes, lack of standardized referral approach, misaligned policy limited resources, and lack of palliative care expertise. Purpose In consideration of these barriers, a description of the development and implementation of an early palliative care initiative at CancerCare Manitoba in Canada is presented. Explanations of innovative planning, processes, teams, and interventions are offered to facilitate insight for those intending to offer early palliative care. Discussion Barriers and facilitators to integrating a nurse-led early palliative care initiative are discussed. Considerations to mitigate common barriers encountered and leveraging existing resources are offered. Conclusions This information may be beneficial to those working to facilitate access to palliative care in oncology for patients with advanced cancers. This model has been successful at our institution with pre and post implementation data presented in an upcoming publication.
The Multinational Association for Supportive Care (MASCC) recently published its Supportive Care 2030 Movement with the aims of developing consensus about shared, equitable and translatable ambitions to drive excellence in and outline the desired state of supportive cancer care by 2030. In response to the publication of the ambition statements, the major oncology nursing organizations launched a collaboration in June 2024 with the aim of achieving global nursing excellence and leadership within the wider interdisciplinary model of supportive cancer care. This editorial presents our collective response to the ambitions set by the Supportive Care 2030 Movement. We believe that the 13 ambitions can realistically be achieved only if five prerequisites are in place that put oncology nursing at the forefront of any relevant endeavor.
The 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Winnipeg, Manitoba, on 26–27 October 2023. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; oncology nurses; pharmacists; and a family physician in oncology (FPO) participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of gastroesophageal cancers.